Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-087-0 | CAS number: 133-06-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June 1989 and October 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
- Objective of study:
- excretion
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Reference substance name:
- Captan
- EC Number:
- 205-087-0
- EC Name:
- Captan
- Cas Number:
- 133-06-2
- Molecular formula:
- C9H8Cl3NO2S
- IUPAC Name:
- 2-[(trichloromethyl)sulfanyl]-2,3,3a,4,7,7a-hexahydro-1H-isoindole-1,3-dione
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- - Physical state: white powder
RADIOLABELLED TEST SUBSTANCE
- Position of radiolabel: [14C]-cyclohexene ring-labelle
d- Specific activity: 769.6 MBq/mmol
- Source: ICI Americas, Western Research Center, Richmond, USA
- Batch number: Y01716/013/001
- Radiochemical purity: >95%
NON RADIOLABELLED TEST SUBSTANCE
- Source: ICI Agrocheinlcals, Jealott's Hill Research Station, Bracknell, Berkshire, UK
- Batch number: Y01716/012/001
- Purity: 99.9%
- Storage: at approximately 4°C in darkness - Radiolabelling:
- yes
- Remarks:
- [14C]-cyclohexene ring-labelled
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- TEST ANIMALS- Source: Charles River, Margate, Kent, UK
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Age at study initiation: young adult- Weight at study initiation: weight range 202-243g- Housing: In multiples by sex in stock rat cages- Diet: free access to PCD diet (Special Diets Services Ltd, Stepfield, Hitham, Essex, UK)- after dosing: the males numbered 1-5 and the females numbered 6-10 were housed Individually In steel metabolism cages (Modular Systems and Developments Company Ltd, Woolwich, London, UK- Water (e.g. ad libitum): both prior to and during the study- Acclimation period: 5 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 16-22°C- Humidity (%): 34-70%- Photoperiod: Lighting conditions in the animal room were controlled with alternate 12 hour light and dark cycles.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: vehicle of 0.7% carboxymethyl cellulose (CMC) in 0.5% Tween 80, dosing volume 4 mL/kg bw
- Details on exposure:
- Dosing: Rats 1-8 and 10 were each given a bodywelght dependent single oral dose of dosing preparation 1, using a gas tight syringe(Hamilton, Bonaduz) fitted with a metal catheter. The dose rate was 4ml/kg which was equivalent to a nominal dose of 10 mg of test substance per kgand 2MBq/kg. The weight of dose administered to each rat was determined by weighing the syringe-catheter assoably prior to and immediately following dosing. Rat 11 was similarly dosed with dosing preparation 2.Dosing preparation 1 was prepared as follows:90.8 mg of CMC was dissolved In 10ml of 0.5% Tween 80 which served as a stock solution. 23.1mg of unlabelled captan and 4.8MBq [14C]-labelled captan was dispersed in 2ml of 0.5% Tween 80. To this 8ml CMC stock solution was added to achieve a final volume of 10ml. The concentration of captan In the dosing preparation was 2.514 mg/g and 0.483 MBq/g. The specific activity of captan In the dose preparation was 0.192 KBq/µg of captan.Dosing preparation 2 was prepared as follows:131.3 mg of CMC was dissolved In 15ml of 0.5% Tween 80 which served as a stock solution. 11.9 mg of unlabelled captan and 2.4 MBq [14C]-labelled captan was dispersed in 1ml of 0.5% Tween 80. To this 4ml CMC stock solution was added to achieve a final volume of 5ml. The concentration of captan In the dosing preparation was 2.649 mg/g and 0.502MBq/g. The specific activity of captan in the dose preparation was 0.190KBq/µg of captan.The dose vehicle was 0.7% carboxymethyl cellulose (CMC) in 0.5% Tween 80. Carboxymethyl cellulose, CTL reference Y06777/001, was obtained from BDH Ltd, UK and 0.5% Tween 80 from ICl Pharmaceuticals, Alderley Park, Cheshire, UK. Liquid scintillation chemicals (OPTIPHASE "MP" \ OPTISORB 'S' and OPTISORB "I"), were obtained from LKB Instruments Ltd, Croydon, UK. HIONIC-FLUOR sclntillant, SOLUENE-350 and C0MBUSTAID were obtained from Canberra Packard Ltd, Pangbourne, Berks, UK. All other chemicals were of analytical grade or of the best grade available.
- Duration and frequency of treatment / exposure:
- one single dose / seven days exposure
Doses / concentrations
- Dose / conc.:
- 10 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- 10 rats (5 male/ 5 female) per dose
- Control animals:
- no
- Details on dosing and sampling:
- Urine and faeces were separately collected at 6, 12, 24, 36 and 48 hours and then at 24 hourly Intervals until 7 days after dosing. Excreta were collected frozen over dry Ice and retained at -20°C prior to analysis.
Results and discussion
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- The mean total recovery of radioactivity was 91.8% (ranging from 73.6 to 107.3%) in males and 90.8% (ranging from 67.4 to 118.2%) in male and female rats, respectively. Majority of radioactivity excreted in the urine after 24 hours.
- Type:
- distribution
- Results:
- The highest concentration of radioactivity was present in the kidneys where mean levels were equivalent to 0.079 µg equivalent captan/g and 0.099 µg equivalent/g captan in males and females, respectively.
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- The levels of radioactivity in tissues 7 days following the administration of [14C]-ring labelled-captan were negligible in most tissues and were either at or below the limit of detection. The highest concentration of radioactivity was present in the kidneys where mean levels were equivalent to 0.079 µg equivalent captan/g and 0.099 µg equivalent/g captan in males and females, respectively. This is consistent with the role of this organ in the excretion of captan. The levels present in the kidneys correspond to only 0.008 and 0.009% of the administered dose, respectively. In both male and female rats the total percentage of administered radioactivity remaining in the tissues was <0.06% and in the carcass was <0.45%.
- Details on excretion:
- The excretion profiles for male and female rats were found to be similar with the majority of radioactivity excreted in the urine after 24 hours. Over the first 24 hours after dosing, 77.2 and 7.4% of the administered radioactivity was excreted via the urine and faeces, respectively, in males and 71% and 6.2% of the administered dose was excreted in the urine and faeces, respectively, in females.
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
Table 7.1-1 Summary of urinary and faecal excretion in male and female rats following a single oral administration of [14C]-captan (10 mg/kg)
Time post dose (hours) |
Percentage administered radioactivity |
|||||||
Male |
Female |
|||||||
Urine |
Faeces |
Cage wash |
Total |
Urine |
Faeces |
Cage wash |
Total |
|
0-6 |
17.1 ± 4.7 |
0.4 ± 0.3 |
- |
- |
6.2 ± 4.6 |
NS |
- |
- |
6-12 |
28.2 ± 3.7 |
2.4 ± 0.7 |
- |
- |
33.8 ± 11.6 |
2.1 ± 1.5 |
- |
- |
12-24 |
31.9 ± 7.9 |
4.6 ± 0.7 |
- |
- |
31.0 ± 10.6 |
4.1 ± 1.0 |
- |
- |
24-36 |
3.4 ± 1.3 |
1.4 ± 0.5 |
- |
- |
5.1 ± 3.3 |
1.3 ± 0.6 |
- |
- |
36-48 |
0.6 ± 0.2 |
0.3 ± <0.1 |
- |
- |
5.0 ± 8.9 |
0.5 ± 0.5 |
- |
- |
48-72 |
0.3 ± 0.1 |
0.1 ± <0.1 |
- |
- |
0.6 ± 0.7 |
0.3 ± 0.3 |
- |
- |
72-96 |
0.1 ± <0.1 |
0.1 ± <0.1 |
- |
- |
0.2 ± 0.1 |
0.2 ± 0.2 |
- |
- |
96-120 |
<0.1 |
<0.1 |
- |
- |
0.1 ± <0.1 |
<0.1 |
- |
- |
120-144 |
<0.1 |
<0.1 |
- |
- |
<0.1 |
<0.1 |
- |
- |
144-168 |
<0.1 |
<0.1 |
- |
- |
<0.1 |
<0.1 |
- |
- |
0-168 |
81.9 ± 13.0 |
9.5 ± 1.7 |
<0.1 |
91.4 ± 14.6 |
82.0 ± 19.6 |
8.5 ± 1.8 |
0.2 ± 0.2 |
90.07 ± 21.0 |
Table 7.1-1 Summary of tissue concentration of radioactivity in male and female rats seven days following a single oral administration of [14C]-ring - labelled-captan (10 mg/kg bw)
Tissue |
Male |
Female |
||
% Dose |
µg equivalent captan/g |
% Dose |
µg equivalent captan/g |
|
Brain |
<0.001 |
<0.018 |
<0.001 |
<0.020 |
Gonads |
0.001 ± <0.001 |
<0.018 |
0.000 |
<0.015 |
Heart |
<0.001 |
<0.029 |
<0.001 |
<0.029 |
Kidneys |
0.008 ± 0.002 |
0.079 ± 0.014 |
0.009 ± 0.002 |
0.099 ± 0.024 |
Liver |
0.009 ± 0.002 |
<0.020 |
0.006 ± 0.003 |
<0.020 |
Lungs |
0.001 ± <0.001 |
<0.024 |
0.002 ± 0.001 |
<0.029 |
Spleen |
<0.001 |
<0.032 |
<0.001 |
<0.043 |
Uterus |
- |
- |
<0.001 |
<0.051 |
Stomach* |
0.011 ± 0.003 |
0.034 ± 0.020 |
0.010 ± 0.005 |
0.038 ± 0.012 |
Small intestine* |
0.018 ± 0.003 |
<0.028 |
0.014 ± 0.004 |
<0.030 |
Large intestine* |
0.005 ± <0.001 |
<0.025 |
0.007 ± 0.003 |
<0.033 |
Bone |
- |
<0.028 |
- |
<0.030 |
Fat |
- |
<0.023 |
- |
<0.039 |
Muscle |
- |
<0.032 |
- |
<0.035 |
Blood |
- |
0.054 ± <0.005 |
- |
0.050 ± 0.009 |
Plasma |
- |
<0.023 |
- |
<0.024 |
Carcass |
0.337 ± 0.088 |
0.036 ± 0.009 |
0.448 ± 0.294 |
0.055 ± 0.039 |
TOTAL |
0.391 ± 0.089 |
|
0.496 ± 0.296 |
|
* These tissues include contents.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results. Following a single oral dose of [14C]-cyclohexene ring-labelled captan (10 mg/kg bw), radioactivity was rapidly excreted. The majority of radioactivity was excreted in the urine with only low levels excreted in the faeces, virtually no retention in the tissues or metabolism to exhaled carbon dioxide. There was no sex difference in the rate or route of elimination of captan, with urinary excretion predominating in both sexes and elimination essentially completed by 48 hours.
- Executive summary:
Five male and five female rats were each given a single oral dose of 10mg [14C]-cyclohexene-labelled captan/kg. The urinary and faecal excretion of radioactivity was monitored over a period of 7 days, following which the residual concentrations of radioactivity were measured in selected tissues.
The excretion profiles of male and female rats were similar, with the urinary route predominating in both sexes. Male rats excreted a mean total of 81.2% of the administered radioactivity in the urine and a mean total of 9.1% In the faeces over a period of 48 hours. Female rats excreted a mean total of 81.1% of the administered radioactivity in the urine and a mean total of 8.0% in the faeces over the same period. Exhaled carbon dioxide measured in one female rat showed <0.14% dose being excreted by this route.
The tissue residual concentrations were negligible in both sexes with the highest concentrations being present in the kidneys (<0.10 µg equivalents captan/g) which corresponded to <0.01% of the total radioactivity dosed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.